NEWS: Earnings
Cellectis Reports Financial Results for First Quarter 2024
Cellectis reported its Q1 2024 financial results revealing key business updates and financial highlights. Key points include:
Completion of a $140M equity investment by AstraZeneca, pushing the company's cash position to $143M as of March 31, 2024, and extending its cash runway projection into 2026.
Revenues for Q1 2024 were $6.5M, a significant increase from $3.6M in Q1 2023.
R&D expenses rose to $22.3M from $21.1M, while SG&A expenses were relatively stable at $5.1M.
The company recorded a consolidated net income of $5.6M, compared to a net loss of $30.1M in Q1 2023.
Key clinical programs BALLI-01, NATHALI-01, and AMELI-01 continue to progress with updates expected by year-end 2024.
The appointment of Arthur Stril as Interim CFO was announced, and AstraZeneca now owns approximately 44% of Cellectis' share capital.
Completion of a $140M equity investment by AstraZeneca, pushing the company's cash position to $143M as of March 31, 2024, and extending its cash runway projection into 2026.
Revenues for Q1 2024 were $6.5M, a significant increase from $3.6M in Q1 2023.
R&D expenses rose to $22.3M from $21.1M, while SG&A expenses were relatively stable at $5.1M.
The company recorded a consolidated net income of $5.6M, compared to a net loss of $30.1M in Q1 2023.
Key clinical programs BALLI-01, NATHALI-01, and AMELI-01 continue to progress with updates expected by year-end 2024.
The appointment of Arthur Stril as Interim CFO was announced, and AstraZeneca now owns approximately 44% of Cellectis' share capital.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment